Loading Events
Find Events

Event Views Navigation

Upcoming Events

Events List Navigation

June 2017

3rd Congress of the European Academy of Neurology

June 24 - June 27

These are exciting times for Neurology. New diseases are being defined, new procedures are developed and introduced in clinical practice resulting in more accurate diagnosis, disease mechanisms are more and more unravelled, and treatment options are extending. Parallel to all these developments also new challenges are encountered in the search for understanding, preserving and repairing the nervous system. These and other topics will be addressed by leading international experts in the different neurological fields. And all will take place in a magnificent town! This 3rd EAN Congress will bring together thousands of scientists and clinicians from all over Europe and the rest of the world. The Programme Committee has prepared an outstanding programme with high quality scientific sessions meeting the hot spots of development and attractive teaching courses covering topics which are most important for the practising neurologist.

Find out more »

Cycle 2: NIH Academic Research Enhancement Award (R15)

June 25

Sponsor: National Institutes of Health
Due Date: June 25, 2017 by 5 pm local time of applicant organization
Award: Direct costs limited to $300,000 over a maximum of 3 years.

Find out more »

HHMI Investigator Program

June 27

Sponsor: Howard Hughes Medical Institute
Due Date: June 27, 2017, 3 p.m. EDT
Award: Each investigator receives his or her full salary, benefits, and a research budget from HHMI. Appointment is for a seven-year term, which may be renewed after an exacting review process.

Find out more »
July 2017

SEB Gothenburg 2017

July 3 - July 6
Swedish Exhibition and Congress Centre, Mässans Gata/Korsvägen
412 94 Göteborg, Sweden

Renowned for creating chemistry through ideas, people and scientific theories, SEB’s Annual Meeting will challenge your mind and increase your connections. Network with around 800 colleagues from across the globe and choose from a whole host of stimulating sessions. Listen and debate with world-class experimental biologists and take part in the exciting social events that will be on offer.

Find out more »

3rd Neurological Disorders Summit (NDS-2017)

July 6 - July 8

3rd Neurological Disorders Summit (NDS-2017) will provide a dedicated platform to share cutting-edge scientific findings, medical practices and caregiver initiatives related to various Neurological Disorders. The multidisciplinary meeting will bring together the scientific community – principal investigators, scientists, researchers, health professionals, analysts, clinicians, policy makers, industry experts, the well-established and the budding entrepreneurs to create a worldwide dialogue on various aspects and challenges of devastating neurological conditions.

NDS-2017 will engage global audience for the exchange of ideas and perspectives for better understanding of origin, development, clinical and translation science to deliver potential cure for neurological diseases. This international gathering will unravel important results concerning the mechanisms and treatment of Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Stroke, Autism, Migraine and other neurological disorders.

The meeting will be highlighted with some of the top influential personalities involved in solving the mysteries of different neurological disorders. The series of talks, poster presentations, workshops, discussions and networking events will keep participants engaged in learning and making new connections at NDS-2017.

Find out more »

Cycle 1: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3)

July 10

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 10, 2017
Due Date: August 9, 2017
Award: Actual needs; applicants may seek up to one year of UG3 funding. The UH3 phase cannot exceed four years.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

July 10

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 10, 2017
Application Due Date: August 9, 2017
Award: Actual needs; applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II.

Find out more »

American Academy of Neurology 2017 Sports Concussion Conference

July 14 - July 16
Hyatt Regency Jacksonville River Front, 225 E Coastline Dr
Jacksonville, FL 32202 United States

A lineup of exemplary faculty will engage you in discussions about the very latest breakthrough science in the world of sports concussion through a variety of formats, including hands-on workshops and debates.

Find out more »

Cycle 7: NINDS CREATE Bio Discovery Track: Optimization in Preparation for Development of Biotechnology Products and Biologics (U44)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017
Award: Budget not limited but must reflect the actual needs of project. Phase I costs will normally remain under $500,000 over up to 1 year; Phase II will normally remain under $2,000,000 over up to 3 years.

Find out more »

Cycle 7: NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017 by 5 pm local time of applicant
Award: Budgets are not limited but have to reflect the actual needs of the proposed project. UH2 phase should rarely exceed 1M per year and UH3 phase should rarely exceed 1.5M per year.

Find out more »

Cycle 7: NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44)

July 18

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: July 18, 2017
Award: Actual needs should rarely exceed $1,000,000 in total cost per year during the Phase 1 and $1,500,000 in total costs per year during the Phase 2. 2 years for Phase I and up to 3 years for Phase II.

Find out more »

Cycle 2: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes

July 25

Sponsor: Patient-Centered Outcomes Research Institute
LOI Due Date: July 25, 2017
Application Due Date: October 25, 2017
Award: Research Award. The past cycle had direct costs of $10 million.

Find out more »

The 12th World Congress on Neurohypophysial Hormones

July 26 - July 29
Porto Real Resort, Rodovia s/n km 450, BR-101 - Nova Mangaratiba
Mangaratiba , RJ 23860-000 Brazil

Jointly with the International Advisory Committee, we are putting an exciting programme that will span all aspects of oxytocin and vasopressin research from cellular physiology to behaviour. The most recent advances in the field will be presented by leading researchers. There will also be ample opportunity for new and emerging researchers to present their work as part of symposiums, oral presentation programme or at the poster session.

At this time, we invite you to submit proposals for Symposia at WCNH 2017. All proposals must be submitted through the e-mail 12thwcnh@gmail.com from now up to 31 October 2016. The proposals should follow this template form. The submitted symposia proposals will be evaluated by the Local Organizing and the International Advisory Committees, and the selected ones will be announced by 15 November 2016.

Find out more »

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 31

LOI DUE JULY 31, 2017
Preclinical Drug Discovery
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
Seeks to fund biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials. Up to $1.5 million.
Biomarkers Development
Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer’s disease, related dementias, and cognitive aging. $150,000-$300,000/year, 1-2 years.
Prevention Beyond the Pipeline
The ADDF seeks to support prevention drug discovery not covered by most research funders or our current RFPs. Funding can range from $50,000-$100,000 for epidemiological analyses, $150,000-$600,000 for preclinical research, and up to $1.5 million for clinical trials.
Accelerating Drug Discovery for Frontotemporal Degeneration
Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration. Funding can range from $100,000-$150,000 per year, average one year duration.

Find out more »
August 2017

Foundation for Physical Therapy

August 3

DUE AUGUST 3, 2017, NOON EDT
Foundation Research Grant
Funds clinically relevant research by emerging investigators seeking to evaluate the effectiveness of physical therapy interventions. This grant will provide $40,000 for either one or two year projects.
Snyder Research Grant
One $40,000 SRG is to be awarded to support relevant clinical research projects aimed to investigate: a) those services delivered by physical therapists; and b) the development of new interventions that offer reasonable assurance that they will be clinically relevant and therapeutically effective.

Find out more »

Cycle 2: Ruth L. Kirschstein National Research Service Awards (F Series)

August 8

Sponsor: National Institutes of Health
Due Date: August 8, 2017
Award: Fellowship

Find out more »

Cycle 2: Conference Grants (R13) and Conference Cooperative Agreements (U13)

August 12

Sponsor: NIH
Due Date: August 12, 2017
Award: Funding for conferences

Find out more »

APS Conference: Physiological Bioenergetics: Mitochondria from Bench to Bedside

August 30 - September 1
U.S. Grant Hotel, 326 Broadway
San Diego, CA 92101 United States

In the last two decades it has become apparent that mitochondria perform a multitude of functions to maintain cellular homeostasis, all of which are intimately linked to bioenergetics. New cutting edge technology, novel molecular tools and mitochondrially targeted therapeutics developed in the past five years have made it possible to more accurately and deeply probe mitochondrial function and have dramatically altered the study of bioenergetics under physiological conditions.

Our knowledge of the mechanisms by which mitochondrial function is regulated and its contribution to cellular homeostasis is also rapidly expanding. However, these advances are generally made in the context of a specific pathology or organ system and are not always widely recognized by investigators studying a different pathology. Further, a great gap in knowledge still exists in translating mitochondrial measurement to human studies.

The goal of the “Physiological Bioenergetics- from Bench to Bedside” conference is to bring together experts studying varied facets of bioenergetics across disciplines and in the context of different pathologies to share their most recent findings and to discuss strategies to advance the field of “mitochondriology” into translational and clinical studies. This is a “”must attend”” conference for a researcher at any stage of their career who is interested in studying mitochondrial function or integrated bioenergetics.

Find out more »
September 2017

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »
+ Export Events